Biosimilar giant Biocon gets hit with 483 for issues at sites in Malaysia and India

Tyler Patchen

News Reporter

While Biocon continues to be one of the major players in the generics and biosimilars markets, several of the company’s manufacturing sites have ended up …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Biosimilar giant Biocon gets hit with 483 for issues at sites in Malaysia and India

Tyler Patchen

News Reporter

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

Why did Eli Lilly ask a patient on a compounded GLP-1 drug for their medical information?

Biotech VC firm outlines plans for $100M fund

FDA OKs the first-ever self-administered vaccine, for flu

FTC to sue major PBMs over insulin rebates, claiming they inflated patient cost

Novo says its CB1 drug helped shed weight, but efficacy and safety questions remain

Breaking down silos with a new quantitative approach to drug development

Biosim­i­lar gi­ant Bio­con gets hit with 483 for is­sues at sites in Malaysia and In­dia

News Reporter

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Biosimilar giant Biocon gets hit with 483 for issues at sites in Malaysia and India